KIF2C as a potential therapeutic target: insights from lung adenocarcinoma subtype classification and functional experiments
Molecular Omics · 2024
DOI: 10.1039/d4mo00044g ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Omics, 2024. Verfasst von Zhi Xu und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Anhui University of Science and Technology, Chongren Building, No 168, Taifeng St, Huainan, 232001, P. R. China. Hauptthemen laut MEDLINE: Kinesins, Adenocarcinoma of Lung, Lung Neoplasms, Epithelial-Mesenchymal Transition. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Anhui University of Science and Technology.
Abstract (Originalsprache)
Objective: this study evaluates the prognostic relevance of gene subtypes and the role of kinesin family member 2C (KIF2C) in lung cancer progression. Methods: high-expression genes linked to overall survival (OS) and progression-free interval (PFI) were selected from the TCGA-LUAD dataset. Consensus clustering analysis categorized lung adenocarcinoma (LUAD) patients into two subtypes, C1 and C2, which were compared using clinical, drug sensitivity, and immunotherapy analyses. A random forest algorithm pinpointed KIF2C as a prognostic hub gene, and its functional impact was assessed through various assays and in vivo experiments.
Results
The study identified 163 key genes and distinguished two LUAD subtypes with differing OS, PFI, pathological stages, drug sensitivity, and immunotherapy response. KIF2C, highly expressed in the C2 subtype, was associated with poor prognosis, promoting cancer cell proliferation, migration, invasion, and epithelial–mesenchymal transition (EMT), with knockdown reducing tumor growth in mice.
Conclusion
The research delineates distinct LUAD subtypes with significant clinical implications and highlights KIF2C as a potential therapeutic target for personalized treatment in LUAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Medicine, Anhui University of Science and Technology, Chongren Building, No 168, Taifeng St, Huainan, 232001, P. R. China.
- Anhui Province Engineering Laboratory of Occupational Health and Safety, Anhui University of Science and Technology, Huainan, 232001, P. R. China.
- Department of Clinical Laboratory, Anhui Zhongke Gengjiu Hospital, Hefei, 230041, P. R. China.
- Key Laboratory of Industrial Dust Prevention and Control & Occupational Safety and Health of the Ministry of Education, Anhui University of Science and Technology, Huainan, 232001, P. R. China.
Förderung
- Anhui University of Science and Technology
Zitieren
APA
Xu, Z., Miao, R., Han, T., Liu, Y., Zhou, J., Guo, J., Xing, Y., Bai, Y., Wu, J., & Hu, D. (2024). KIF2C as a potential therapeutic target: insights from lung adenocarcinoma subtype classification and functional experiments. Molecular Omics. https://doi.org/10.1039/d4mo00044g
Vancouver
Xu Z, Miao R, Han T, Liu Y, Zhou J, Guo J, et al. KIF2C as a potential therapeutic target: insights from lung adenocarcinoma subtype classification and functional experiments. Molecular Omics. 2024. doi:10.1039/d4mo00044g
BibTeX
@article{Xu2024,
author = {Xu, Zhi and Miao, Rui and Han, Tao and Liu, Yafeng and Zhou, Jiawei and Guo, Jianqiang and Xing, Yingru and Bai, Ying and Wu, Jing and Hu, Dong},
title = {KIF2C as a potential therapeutic target: insights from lung adenocarcinoma subtype classification and functional experiments},
journal = {Molecular Omics},
year = {2024},
doi = {10.1039/d4mo00044g}
}
EUVIMED